Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3373569 | 0.91 | NPSR1 (0.40) | NPSR1L3MBTL1ALOX15CA12CA9 | |
| SCHEMBL2891988 | 0.90 | NPSR1 (0.41) | NPSR1L3MBTL1PTPN1ALOX15CA12 | |
| SCHEMBL3377641 | 0.88 | NPSR1 (0.40) | NPSR1L3MBTL1PTPN1ALOX15CA12 | |
| SCHEMBL3377691 | 0.86 | NPSR1 (0.42) | NPSR1L3MBTL1PTPN1ALOX15CA12 | |
| SCHEMBL2891984 | 0.81 | NPSR1 (0.39) | NPSR1L3MBTL1ALOX15CA12CA9 | |
| SCHEMBL3377883 | 0.80 | HCRTR1 (0.41) | NPSR1L3MBTL1KMT2AMEN1 | |
| SCHEMBL550827 | 0.79 | NPSR1 (0.55) | NPSR1L3MBTL1PTPN1ALOX15CA12 | |
| SCHEMBL3377632 | 0.79 | NPSR1 (0.37) | NPSR1L3MBTL1ALOX15CA12CA9 | |
| SCHEMBL3377960 | 0.79 | MEN1 (0.41) | NPSR1PTPN1POLBKMT2AMEN1 | |
| SCHEMBL550488 | 0.77 | PTPN1 (0.42) | NPSR1L3MBTL1PTPN1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1517886-B1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2010-11-10 | — | — | EP | disclosed |
| US-7132455-B2 | Phthalamide derivatives | BAYER CROPSCIENCE AG (DE) | 2006-11-07 | — | — | US | disclosed |
| US-20060035967-A1 | Novel phthalamide derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-02-16 | — | — | US | disclosed |
| EP-1517886-A1 | NOVEL PHTHALAMIDE DERIVATIVES | Bayer CropScience AG (DE) | 2005-03-30 | — | — | EP | disclosed |
| WO-2004000796-A1 | NOVEL PHTHALAMIDE DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035967-A1 | Novel phthalamide derivatives | HDAC1, HDAC2, CRY1 | NPSR1 918/4885L3MBTL1 1720/4885PTPN1 3309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.